Pharmacological treatment of COVID-19: an opinion paper
A García-Lledó, J Gómez-Pavón… - Revista Española …, 2021 - pmc.ncbi.nlm.nih.gov
The precocity and efficacy of the vaccines developed so far against COVID-19 has been the
most significant and saving advance against the pandemic. The development of vaccines …
most significant and saving advance against the pandemic. The development of vaccines …
Remdesivir: a review in COVID-19
HA Blair - Drugs, 2023 - Springer
Remdesivir (Veklury®), a nucleotide analogue prodrug with broad-spectrum antiviral activity,
is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by …
is approved for the treatment of coronavirus disease 2019 (COVID-19), the illness caused by …
Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis
This network meta-analysis (NMA) assessed the efficacy of remdesivir in hospitalized
patients with COVID-19 requiring supplemental oxygen. Randomized controlled trials of …
patients with COVID-19 requiring supplemental oxygen. Randomized controlled trials of …
The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: A systematic review and meta-analysis
C Chen, J Fang, S Chen, MJN Rajaofera, X Li… - BMC Infectious …, 2023 - Springer
Background Remdesivir is considered to be a specific drug for treating coronavirus disease
2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir …
2019. This systematic review aims to evaluate the clinical efficacy and risk of remdesivir …
Survival benefit of remdesivir in hospitalized COVID-19 patients with high SARS-CoV-2 viral loads and low-grade systemic inflammation
Objectives To assess the benefits of remdesivir in hospitalized COVID-19 patients receiving
combined immunomodulatory therapy (CIT) with dexamethasone and tocilizumab. Methods …
combined immunomodulatory therapy (CIT) with dexamethasone and tocilizumab. Methods …
Effects of remdesivir on SARS-CoV-2 viral dynamics and mortality in viraemic patients hospitalized for COVID-19
K Hagman, M Hedenstierna, J Widaeus… - Journal of …, 2023 - academic.oup.com
Background Studies on the antiviral effects of remdesivir have shown conflicting results.
SARS-CoV-2 viraemia could identify patients in whom antiviral treatment may be particularly …
SARS-CoV-2 viraemia could identify patients in whom antiviral treatment may be particularly …
Early use of remdesivir and risk of disease progression in hospitalized patients with mild to moderate COVID-19
Purpose Preliminary data suggest that remdesivir may influence the course of COVID-19
according to the duration of pre-admission symptoms. We aim to evaluate whether early use …
according to the duration of pre-admission symptoms. We aim to evaluate whether early use …
[HTML][HTML] Antiviral drugs against SARS-CoV-2
The use of antiviral drugs represents an important progress in the therapeutic management
of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and …
of COVID-19, leading to a substantial reduction of SARS-CoV-2-related complications and …
Current outcomes of SARS-CoV-2 Omicron variant infection in high-risk haematological patients treated early with antivirals
Objectives We aimed to describe the clinical outcomes and duration of viral shedding in high-
risk patients with haematological malignancies hospitalized with COVID-19 during Omicron …
risk patients with haematological malignancies hospitalized with COVID-19 during Omicron …
Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses
R Alonso-Navarro, M Ramírez, M Masiá… - BMC infectious …, 2023 - Springer
Background Shorter duration of symptoms before remdesivir has been associated with
better outcomes. Our goal was to evaluate variables associated with the need of ICU …
better outcomes. Our goal was to evaluate variables associated with the need of ICU …